Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Recruiting 3Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Gynecologic 31Gastrointestinal 24Thoracic 16Head & Neck 9Tumor-Agnostic 7Sarcoma 6Other solid neoplasm 5Dermatologic 5Breast 5Genitourinary 3CNS 3Plasma cell 2Endocrine 2Lymphoid 1

Conditions

Neoplasms 6Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × dostarlimab × Tumor-Agnostic × Clear all
NCT06551142 2026-05-22

PanTumor-101

GlaxoSmithKline

Phase 1 Recruiting
845 enrolled
Tumor-Agnostic

Neoplasms

NCT06796907 2026-05-22

BEHOLD-2

GlaxoSmithKline

Phase 1/2 Recruiting
305 enrolled
Tumor-Agnostic

Neoplasms

NCT04446351 2025-10-27

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

GlaxoSmithKline

Phase 1 Active not recruiting
107 enrolled
Tumor-Agnostic

Neoplasms

NCT06926673 2025-07-03

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

GlaxoSmithKline

Phase 2 Completed
62 enrolled 36 charts
Tumor-Agnostic

Neoplasms

NCT02723955 2024-12-27

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

GlaxoSmithKline

Phase 1 Completed
829 enrolled 100 charts
Tumor-Agnostic

Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

Oslo University Hospital

Phase 2 Recruiting
3,000 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03308942 2023-10-16

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Tesaro, Inc.

Phase 2 Completed
53 enrolled 35 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡